Objective:The main aim is to evaluate the value of dynamic contrast-enhanced (DCE) imaging in multi-parametric prostate MRI (mpMRI) for the detection and staging of prostate cancer in comparison with T2W and DWI images alone in biparametric MRI (bpMRI), in treatment nau00efve patients.Methods:One hundred consecutive patients who underwent a prostate MRI at our institution from June-August 2017, as well as a systematic ultrasound-guided prostate biopsy or prostatectomy, were included. Strictly following the PIRADSv2, the MRI studies were independently interpreted by a body radiologist and a body-imaging fellow on two different occasions 8-10 weeks apart. Initially, with all mpMRI sequences and then without the DCE sequence (bpMRI). The readers were blinded to the clinical information. Ethics approval was obtained.Results/Discussion:One hundred treatment-nau00efve patients were included (median age 64, age range 48-81, mean PSA 10.3). There was excellent intra-observer agreement of the mpMRI versus bpMRI for both readers [Cohenu2019s Kappa (k) 0.88-0.86] and very good inter-observer agreement (k=0.74 for mpMRI and 0.76 for bpMRI). The sensitivity and specificity did not significantly change between the multi-parametric and bi-parametric MRI (Sensitivity 91.7% and 90%, Specificity of 85.5% and 85% for mpMRI and bpMRI, respectively).Conclusion:Prostate MRI without DCE (bpMRI) is of comparable diagnostic accuracy to mpMRI in treatment-nau00efve patients. Performing prostate MRI without DCE (bpMRI) will reduce acquisition time, decrease cost and potentially improve patient safety.

This book covers novel strategies and state of the art approaches for automated non-invasive systems for early prostate cancer diagnosis. Prostate cancer is the most frequently diagnosed malignancy after skin cancer and the second leading cause of cancer related male deaths in the USA after lung cancer. However, early detection of prostate cancer increases chances of patients’ survival. Generally, The CAD systems analyze the prostate images in three steps: (i) prostate segmentation; (ii) Prostate description or feature extraction; and (iii) classification of the prostate status. Explores all of the latest research and developments in state-of-the art imaging of the prostate from world class experts. Contains a comprehensive overview of 2D/3D Shape Modeling for MRI data. Presents a detailed examination of automated segmentation of the prostate in 3D imaging. Examines Computer-Aided-Diagnosis through automated techniques. There will be extensive references at the end of each chapter to enhance further study.

MRI Atlas of Prostate Cancer analyses high-resolution MRI scanning and dynamic contrast-enhanced (DCE) MRI. This combination improves the diagnosis and staging of prostate cancer and may soon replace PSA testing and digital rectal examination. The first two chapters focus on normal anatomy, anatomic variations, benign disease and intraprostatic tumors. The subsequent chapters on MRI of extracapsular disease create a useful atlas of pathologic anatomy. This is the first text of its kind to show color-coded DCE-MRI scans of prostate cancer and to correlate these imaging findings with tumor grading. The chapters on the post-treatment prostate clearly display the increasing incidence of post-therapy recurrences. This book is intended for internists, radiologists, radiotherapists, oncologists, urologists, family practitioners, and general surgeons. Ultrasound, MRI, and radiotherapy technicians will find it extremely useful as a reference guide.

This pocket book explains the significant and well-documented impact that PET/CT can have on the management of prostate cancer through the provision of high-quality evidence regarding function and structure. Up-to-date information is supplied on the relevance of PET/CT to diagnosis, treatment planning, and therapy, including the emerging role of PET/CT with PSMA. Readers will also find clear explanation of the relation of the clinical and pathological background to imaging and the value of PET/CT compared with conventional radiological imaging. The book will be an excellent asset for referring clinicians, nuclear medicine/radiology physicians, radiographers/technologists, and nurses who routinely work in nuclear medicine and participate in multidisciplinary meetings. It is published within the Springer series Clinicians’ Guides to Radionuclide Hybrid Imaging, which presents contributions from professionals worldwide who share a common purpose in promoting nuclear medicine as an important imaging specialty for the diagnosis and management of oncological and non-oncological conditions.

This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.

"This book admirably covers prostate cancer. It is written in an easily digestible manner for non-experts and emphasizes the importance of a team approach to treatment of patients with this disease."--Doody's Reviews With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice. The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life. A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study. Key Features: Delineates a practical, concise approach to multidisciplinary management of prostate cancer Provides a wide range of perspectives and expertise Written and edited by an international, multidisciplinary team of prostate cancer specialists Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data

This atlas provides a comprehensive, state of the art review of the use of multiparametric MRI (mpMRI) for the imaging of prostate cancer, covering aspects from diagnosis and loco-regional staging through to the role of the technique after treatment and follow-up. The book contains a wealth of high-resolution images, many of them in color, and displays the anatomical-MRI–pathological correlation whenever appropriate. Readers will find a helpful overview on the current standardized method for reading and reporting on mpMRI, the Prostate Imaging Reporting and Data System (PI-RADS), version 2. Dedicated chapters focus on differential diagnosis and imaging pitfalls, and the inclusion of helpful diagrams and algorithms will further assist in image interpretation, enabling readers to ease and improve their use of mpMRI. Edited and written by very experienced radiologists, pathologists, and urologists; the Atlas of Multiparametric Prostate MRI will serve as a unique source of clinically relevant information and an aid to disease management for radiologists, urologists, pathologists, radiotherapists, and oncologists.